|
1
|
Rubin SC, Blackwood MA, Bandera C, et al:
BRCA 1, BRCA 2, and hereditary nonpolyposis colorectal cancer gene
mutations in an unselected ovarian cancer population: relationship
to family history and implications for genetic testing. Am J Obstet
Gynecol. 178:670–677. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Struewing JP, Hartge P, Wacholder S, et
al: The risk of cancer associated with specific mutations of BRCA1
and BRCA2 among Ashkenazi Jews. N Engl J Med. 336:1401–1408. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boyd J, Sonoda Y, Federici MG, et al:
Clinicopathologic features of BRCA-linked and sporadic ovarian
cancer. JAMA. 283:2260–2265. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Werness BA, Ramus SJ, DiCioccio RA, et al:
Histopathology, FIGO stage, and BRCA mutation status of ovarian
cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int
J Gynecol Pathol. 23:29–34. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pal T, Permuth-Wey J, Betts JA, et al:
BRCA1 and BRCA2 mutations account for a large proportion of ovarian
carcinoma cases. Cancer. 104:2807–2816. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peltomaki P and Vasen H: Mutations
associated with HNPCC predisposition - Update of ICG-HNPCC/INSiGHT
mutation database. Dis Markers. 20:269–276. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Banno K, Yanokura M, Kobayashi Y, et al:
Endometrial cancer as a familial tumor: pathology and molecular
carcinogenesis (review). Curr Genomics. 10:127–132. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hirata K, Kanemitsu S, Nakayama Y, et al:
A novel germline mutation of MSH2 in a hereditary nonpolyposis
colorectal cancer patient with liposarcoma. Am J Gastroenterol.
101:193–196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Banno K, Kisu I, Yanokura M, et al:
Epimutation and cancer: A new carcinogenic mechanism of Lynch
syndrome (Review). Int J Oncol. 41:793–797. 2012.PubMed/NCBI
|
|
10
|
Aarnio M, Sankila R, Pukkala E, et al:
Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int
J Cancer. 81:214–218. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dunlop MG, Farrington SM, Carothers AD, et
al: Cancer risk associated with germline DNA mismatch repair gene
mutations. Hum Mol Genet. 6:105–110. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Broaddus RR, Lynch HT, Chen LM, et al:
Pathologic features of endometrial carcinoma associated with HNPCC:
a comparison with sporadic endometrial carcinoma. Cancer.
106:87–94. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Watson P, Butzow R, Lynch HT, et al: The
clinical features of ovarian cancer in hereditary nonpolyposis
colorectal cancer. Gynecol Oncol. 82:223–228. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
National Comprehensive Cancer Network
(NCCN) Clinical Practice Guidelines in Oncology, . Genetic/familial
high-risk assesment: breast and ovarian. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdfAccessed.
January 2–2014
|
|
15
|
Ford D, Easton DF, Stratton M, et al:
Genetic heterogeneity and penetrance analysis of the BRCA1 and
BRCA2 genes in breast cancer families. The Breast Cancer Linkage
Consortium. Am J Hum Genet. 62:676–689. 1998. View Article : Google Scholar
|
|
16
|
King MC, Marks JH and Mandell JBNew York
Breast Cancer Study Group: Breast and ovarian cancer risks due to
inherited mutations in BRCA1 and BRCA2. Science. 302:643–646. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Finch AP, Lubinski J, Moller P, et al:
Impact of oophorectomy on cancer incidence and mortality in women
with a BRCA1 or BRCA2 mutation. J Clin Oncol. Feb 24–2014.(Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kauff ND, Mitra N, Robson ME, et al: Risk
of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary
breast cancer families. J Natl Cancer Inst. 97:1382–1384. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
National Comprehensive Cancer Network
(NCCN) Clinical Practice Guidelines in Oncology, . Colorectal
cancer screening. http://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdfAccessed.
October 2–2014
|
|
20
|
Schmeler KM, Lynch HT, Chen LM, et al:
Prophylactic surgery to reduce the risk of gynecologic cancers in
the Lynch syndrome. N Engl J Med. 354:261–269. 2006. View Article : Google Scholar
|
|
21
|
Meyer LA, Broaddus RR and Lu KH:
Endometrial cancer and Lynch syndrome: clinical and pathologic
considerations. Cancer Control. 16:14–22. 2009.PubMed/NCBI
|
|
22
|
Offit K and Kauff ND: Reducing the risk of
gynecologic cancer in the Lynch syndrome. N Engl J Med.
354:293–295. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kehoe SM and Kauff ND: Screening and
prevention of hereditary gynecologic cancers. Semin Oncol.
34:406–410. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hirasawa A, Masuda K, Akahane T, et al:
Experience of risk-reducing salpingo-oophorectomy for BRCA1
mutation carrier and establishment of a system performing a
preventive surgery for hereditary breast and ovarian cancer
syndrome in Japan: Our challenges for the future. Jpn J Clin Oncol.
43:515–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kenkhuis MJ, de Bock GH, Elferink PO, et
al: Short-term surgical outcome and safety of risk-reducing
salpingo-oophorectomy in BRCA1/2 mutation carriers. Maturitas.
66:310–314. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Escobar PF, Starks DC, Fader AN, Barber M
and Rojas-Espalliat L: Single-port risk-reducing
salpingo-oophorectomy with and without hysterectomy: surgical
outcomes and learning curve analysis. Gynecol Oncol. 119:43–47.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Finch A, Shaw P, Rosen B, Murphy J, Narod
SA and Colgan TJ: Clinical and pathologic findings of prophylactic
salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol
Oncol. 100:58–64. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kauff ND, Satagopan JM, Robson ME, et al:
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or
BRCA2mutation. N Engl J Med. 346:1609–1615. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lavie O, Hornreich G, Ben-Arie A, et al:
BRCA germline mutations in Jewish women with uterine serous
papillary carcinoma. Gynecol Oncol. 92:521–524. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Beiner ME, Finch A, Rosen B, et al: The
risk of endometrial cancer in women with BRCA1 and BRCA2 mutations.
A prospective study. Gynecol Oncol. 104:7–10. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Villella JA, Parmar M, Donohue K, Fahey C,
Piver MS and Rodabaugh K: Role of prophylactic hysterectomy in
patients at high risk for hereditary cancers. Gynecol Oncol.
102:475–479. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lu KH and Broaddus RR: Gynecologic cancers
in Lynch syndrome/HNPCC. Fam Cancer. 4:249–254. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nieboer TE, Johnson N, Lethaby A, et al:
Surgical approach to hysterectomy for benign gynaecological
disease. Cochrane Database Syst Rev. (3):CD0036772009.PubMed/NCBI
|
|
34
|
Lu KH, Dinh M, Kohlmann W, et al:
Gynecologic cancer as a ‘sentinel cancer’ for women with hereditary
nonpolyposis colorectal cancer syndrome. Obstet Gynecol.
105:569–574. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rebbeck TR, Kauff ND and Domchek SM:
Meta-analysis of risk reduction estimates associated with
risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation
carriers. J Natl Cancer Inst. 101:80–87. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Domchek SM, Friebel TM, Singer CF, et al:
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation
carriers with cancer risk and mortality. JAMA. 304:967–975. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen LM, Yang KY, Little SE, Cheung MK and
Caughey AB: Gynecologic cancer prevention in Lynch
syndrome/hereditary nonpolyposis colorectal cancer families. Obstet
Gynecol. 110:18–25. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chapman JS, Powell CB, McLennan J, et al:
Surveillance of survivors: follow-up after risk-reducing
salpingo-oophorectomy in BRCA 1/2 mutation carriers. Gynecol Oncol.
122:339–343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Finch A, Beiner M, Lubinski J, et al:
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and
peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA.
296:185–192. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lindor NM, Petersen GM, Hadley DW, et al:
Recommendations for the care of individuals with an inherited
predisposition to Lynch syndrome: a systematic review. JAMA.
296:1507–1517. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schmeler KM, Daniels MS, Soliman PT, et
al: Primary peritoneal cancer after bilateral salpingo-oophorectomy
in two patients with Lynch syndrome. Obstet Gynecol. 115:432–434.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Anderson GL, Limacher M, Assaf AR, et al
Women's Health Initiative Steering Committee: Effects of conjugated
equine estrogen in postmenopausal women with hysterectomy: the
Women's Health Initiative randomized controlled trial. JAMA.
291:1701–1712. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kauff ND and Barakat RR: Risk-reducing
salpingo-oophorectomy in patients with germline mutations in BRCA1
or BRCA2. J Clin Oncol. 25:2921–2927. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Grady D, Gebretsadik T, Kerlikowske K,
Ernster V and Petitti D: Hormone replacement therapy and
endometrial cancer risk: a meta-analysis. Obstet Gynecol.
85:304–313. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Barakat RR, Bundy BN, Spirtos NM, Bell J
and Mannel RSGynecologic Oncology Group Study: Randomized
double-blind trial of estrogen replacement therapy versus placebo
in stage I or II endometrial cancer: a Gynecologic Oncology Group
Study. J Clin Oncol. 24:587–592. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Beral V, Bull D and Reeves GMillion Women
Study Collaborators: Endometrial cancer and hormone-replacement
therapy in the Million Women Study. Lancet. 365:1543–1551. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Voigt LF, Weiss NS, Chu J, Daling JR,
McKnight B and van Belle G: Progestagen supplementation of
exogenous oestrogens and risk of endometrial cancer. Lancet.
338:274–277. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chlebowski RT, Anderson GL, Gass M, et al:
Estrogen plus progestin and breast cancer incidence and mortality
in postmenopausal women. JAMA. 304:1684–1692. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Eden JA: Why does oestrogen-only hormone
therapy have such a small impact on breast cancer risk? A
hypothesis. Gynecol Endocrinol. 27:170–175. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rebbeck TR, Friebel T, Wagner T, et al
PROSE Study Group: Effect of short-term hormone replacement therapy
on breast cancer risk reduction after bilateral prophylactic
oophorectomy in BRCA1 and BRCA2mutation carriers: the PROSE Study
Group. J Clin Oncol. 23:7804–7810. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Eisen A, Lubinski J, Gronwald J, et al:
Hormone therapy and the risk of breast cancer in BRCA1 mutation
carriers. J Natl Cancer Inst. 100:1361–1367. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Win AK, Young JP, Lindor NM, et al:
Colorectal and other cancer risks for carriers and noncarriers from
families with a DNA mismatch repair gene mutation: a prospective
cohort study. J Clin Oncol. 30:958–964. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sestak I and Cuzick J: Preventive therapy
for breast cancer. Curr Oncol Rep. 14:568–573. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Pickar JH, Yeh IT, Bachmann G and Speroff
L: Endometrial effects of a tissue selective estrogen complex
containing bazedoxifene/conjugated estrogens as a menopausal
therapy. Fertil Steril. 92:1018–1024. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nelson HD, Vesco KK, Haney E, et al:
Nonhormonal therapies for menopausal hot flashes: systematic review
and meta-analysis. JAMA. 295:2057–2071. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Pearce CL, Chung K, Pike MC and Wu AH:
Increased ovarian cancer risk associated with menopausal estrogen
therapy is reduced by adding a progestin. Cancer. 115:531–539.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lacey JV Jr, Brinton LA, Leitzmann MF, et
al: Menopausal hormone therapy and ovarian cancer risk in the
National Institutes of Health-AARP Diet and Health Study Cohort. J
Natl Cancer Inst. 98:1397–1405. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hildebrand JS, Gapstur SM, Feigelson HS,
Teras LR, Thun MJ and Patel AV: Postmenopausal hormone use and
incident ovarian cancer: Associations differ by regimen. Int J
Cancer. 127:2928–2935. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Miller SM, Roussi P, Daly MB and Scarpato
J: New strategies in ovarian cancer: uptake and experience of women
at high risk of ovarian cancer who are considering risk-reducing
salpingo-oophorectomy. Clin Cancer Res. 16:5094–5106. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kuerer HM, Hwang ES, Anthony JP, et al:
Current national health insurance coverage policies for breast and
ovarian cancer prophylactic surgery. Ann Surg Oncol. 7:325–332.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Anderson K, Jacobson JS, Heitjan DF, et
al: Cost-effectiveness of preventive strategies for women with a
BRCA1 or a BRCA2mutation. Ann Intern Med. 144:397–406. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yurgelun MB, Mercado R, Rosenblatt M, et
al: Impact of genetic testing on endometrial cancer risk-reducing
practices in women at risk for Lynch syndrome. Gynecol Oncol.
127:544–551. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ichikawa Y, Hirai Y, Hasumi K and
Utsunomiya J: Prophylactic salpingo-oophorectomy in a woman with
high-risk for ovarian carcinoma: A case report. Kanto J Obstet
Gynecol. 42:9–14. 2005.(In Japanese).
|
|
64
|
Arai M, Iwase H, Nishimura S, Iwase T and
Takizawa K: Risk-reducing surgery for patients with hereditary
breast and ovarian cancer. Jpn Soc Fam Tumors. 12:A272012.(In
Japanese).
|
|
65
|
Nakamura K, Hirasawa A, Akahane T, et al:
A case of Lynch syndrome intervened early after genetic testing.
Tokyo J Obstet Gynecol. 60:293–297. 2011.(In Japanese).
|
|
66
|
Kwong A, Wong CH, Shea C, Suen DT and Choi
CL: Choice of management of southern Chinese BRCA mutation
carriers. World J Surg. 34:1416–1426. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kim D, Kang E, Hwang E, et al: Factors
affecting the decision to undergo risk-reducing
salpingo-oophorectomy among women with BRCA gene mutation. Fam
Cancer. 12:621–628. 2013. View Article : Google Scholar : PubMed/NCBI
|
